A recent study using CML cell lines and IM-resistant patient samples found that autocrine HH signaling may also promote resistance by upregulating BCL-2 (Figure 2) [63]. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.